Free Status Report - District Court of Delaware - Delaware


File Size: 25.0 kB
Pages: 2
Date: December 31, 1969
File Format: PDF
State: Delaware
Category: District Court of Delaware
Author: unknown
Word Count: 413 Words, 2,695 Characters
Page Size: Letter (8 1/2" x 11")
URL

https://www.findforms.com/pdf_files/ded/7523/166.pdf

Download Status Report - District Court of Delaware ( 25.0 kB)


Preview Status Report - District Court of Delaware
Case 1:04-cv-00171-GMS

Document 166

Filed 11/13/2007

Page 1 of 2

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ---------------------------------------------------------------x : GLAXO GROUP LIMITED : : Plaintiff, : v. : : TEVA PHARMACEUTICALS USA, INC. and : TEVA PHARMACEUTICAL INDUSTRIES : LIMITED : : Defendants. : ---------------------------------------------------------------x JOINT STATUS REPORT The parties, plaintiff Glaxo Group Ltd. ("Glaxo") and defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. ("Teva"), submit this Status Report in response to the Court's Order of November 1, 2007 (D.I. 165). The parties completed discovery and filed Markman briefs and summary judgment motions in the summer of 2006. Judge Jordan heard oral argument on the claim construction disputes and summary judgment motions on September 8, 2006. The case was originally scheduled for a bench trial before Judge Jordan in March 2007, but due to Judge Jordan's elevation to the Third Circuit Court of Appeals in December 2006, the trial was postponed. On August 15, 2006, the parties entered into an agreement providing that, inter alia, Teva would not sell its generic drug product until at least ten days after giving Glaxo notice that Teva had received marketing approval from the Food and Dug Administration ("FDA"). The ten day notice period provides Glaxo with the opportunity to file a motion for a Temporary Restraining Order and a Preliminary Injunction in the event such a motion is necessary. As of the date of this Joint Status Report, Teva has not

Civil Action No. 04-171-***

Case 1:04-cv-00171-GMS

Document 166

Filed 11/13/2007

Page 2 of 2

received marketing approval from the FDA for its generic drug product at issue in this case, and has not provided notice of FDA approval to Glaxo. Counsel for the parties are available to discuss this matter at the Court's convenience should the Court so desire. Respectfully submitted,

/s Francis DiGiovanni Francis DiGiovanni (#3189) Connolly Bove Lodge & Hutz LLP The Nemours Building 1007 North Orange Street P.O. Box 2207 Wilmington, DE 19899 (302) 658-9141 Attorneys for Plaintiff OF COUNSEL: Brian P. Murphy Oren D. Langer Morgan Lewis & Bockius LLP 101 Park Avenue New York, NY 10178-0060 (212) 309-6000

/s/ Josy W. Ingersoll Josy W. Ingersoll (#1088) Young Conaway Stargatt & Taylor LLP The Brandywine Building 1000 West Street, 17th Floor P.O. Box 391 Wilmington, DE 19899 (302) 571-6672 Attorneys for Defendants OF COUNSEL: Mark D. Schuman, Esq. Jeffrey C. Brown, Esq. Merchant & Gould LLC 3200 IDS Center 80 South 8th Street Minneapolis, MN 55402 (612) 332-5300

575365v1

2